(Q37259581)

19 August 2017

0 references

Structural differences among cost-effectiveness models of human papillomavirus vaccines (English)

1 reference

cost-effectiveness analysis

19 August 2017

main subject

1 reference

Ralph P Insinga

1

1 reference

19 August 2017

Erik J Dasbach

series ordinal

2

1 reference

19 August 2017

Elamin H Elbasha

series ordinal

3

1 reference

19 August 2017

publication date

1 September 2008

1 reference

Expert Review of Vaccines

19 August 2017

published in

1 reference

19 August 2017

volume

7

1 reference

19 August 2017

issue

7

1 reference

19 August 2017

page(s)

895-913

1 reference

The clinical importance of the nomenclature, evolution and taxonomy of human papillomaviruses

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.895

Global cancer statistics, 2002

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.895

Prevention strategies against the human papillomavirus: the effectiveness of vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.895

Pediatric respiratory papillomatosis: prognostic role of viral typing and cofactors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.895

Clinical presentation and natural course of anogenital warts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.895

Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.895

Model for assessing human papillomavirus vaccination strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.895

Cost-effectiveness of HPV 16, 18 vaccination in Brazil

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.895

Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.895

The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.895

A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.895

Potential health and economic impact of adding a human papillomavirus vaccine to screening programs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.895

Economic evaluations of human papillomavirus vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.895

Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.895

Chapter 21: Modelling the impact of HPV vaccines on cervical cancer and screening programmes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.895

Cost-effectiveness analyses of human papillomavirus vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.895

Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.895

Modeling human papillomavirus vaccine effectiveness: quantifying the impact of parameter uncertainty

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.895

Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.895

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.895

Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.895

A systematic review of the prevalence and attribution of human papillomavirus types among cervical, vaginal, and vulvar precancers and cancers in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.895

Human Papillomavirus Types in Head and Neck Squamous Cell Carcinomas Worldwide: A Systematic Review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.895

Against which human papillomavirus types shall we vaccinate and screen? The international perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.895

Task force on recurrent respiratory papillomas. A preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.895

Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.895

Acquired immune response to oncogenic human papillomavirus associated with prophylactic cervical cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.895

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.895

Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.895

Type-specific duration of human papillomavirus infection: implications for human papillomavirus screening and vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.895

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.895

Diagnoses and outcomes in cervical cancer screening: a population-based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.895

Prevalence of HPV infection among females in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.895

Psychological impact of human papillomavirus testing in women with borderline or mildly dyskaryotic cervical smear test results: cross sectional questionnaire study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.895

Cervical cancer screening program of Paraná: cytohistological correlation results after five years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.895

International incidence rates of invasive cervical cancer after introduction of cytological screening.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.895

Impact of the National Breast and Cervical Cancer Early Detection Program on mammography and Pap test utilization among white, Hispanic, and African American women: 1996-2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.895

Age-period-cohort analysis of cervical cancer mortality in Taiwan, 1974-1992.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.895

International trends in the incidence of cervical cancer: I. Adenocarcinoma and adenosquamous cell carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.895

International trends in incidence of cervical cancer: II. Squamous-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.895

Human papillomavirus: the burden of infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.895

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.895

Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.895

Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.895

21 January 2018

Identifiers

DOI

10.1586/14760584.7.7.895

1 reference

19 August 2017

1 reference